SDG 3. GOOD HEALTH & WELL-BEING Exscientia

Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials

OXFORD, England–(BUSINESS WIRE)–Exscientia, a leading artificial intelligence (AI)-driven pharmatech company, today announced the first AI-designed molecule for immuno-oncology to enter human clinical trials. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, was co-invented and developed through a Joint Venture between Exscientia and Evotec, including application of Exscientia’s next generation 3-D evolutionary AI-design platform as part of C






Read more on Business Wire Technology News

You may also like

Comments are closed.